Moderna on Bioeconhttps://en.bioecon.ru/companies/moderna/Recent content in Moderna on BioeconHugoen-USSat, 11 Jul 2026 14:19:14 +0700Drug & vaccine developmenthttps://en.bioecon.ru/technology/drug-vaccine-development/Sun, 05 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/drug-vaccine-development/The end-to-end R&D pipeline that carries a drug or vaccine candidate from target identification through Phase I-IV clinical trials to regulatory approval — a 7-15-year, billion-dollar process now being reshaped by personalized mRNA platforms, GLP-1 blockbuster economics and competing FDA, EMA and NMPA regulatory-acceleration reforms.mRNA platforms & LNP deliveryhttps://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression.